← Back to headlines
Praxis Therapeutics Sees Action Date Extended for Encephalopathies Asset Relutrigine
Praxis Therapeutics has announced an extension to the action date for its encephalopathies asset, relutrigine, impacting its development timeline.
29 Jun, 22:14 — 29 Jun, 22:14
Sources
Showing 1 of 1 sources
